Hello all! Let’s dive right into today’s newsletter…very exciting stuff to get to.

As always, if you want to follow along or be extra informed before reading this, we recommend you check out the podcast while you read:

Some highlights from today’s newsletter: Gold just ripped 57% this year while trading at 17x its historical CPI ratio—something’s different. Meanwhile, 1 in 8 Americans have tried GLP-1s, creating what might be the first pharmaceutical subscription model with near-zero churn.

Gold just ripped 57% year-to-date. That’s an absolutely insane move for what most people think of as a “safe haven” asset. But here’s what almost everyone gets wrong about gold: it’s not a commodity. It’s a collectible.

Think about it. Commodities like oil or copper get consumed—they have industrial utility. Gold? Gold just sits there. Sure, there’s some jewelry demand, but that’s just wearable social signaling. Gold is closer to Pokémon cards or fine art than it is to steel. It doesn’t produce cash flows. It doesn’t have earnings. It has a price dictated entirely by supply, demand, and—let’s be honest—vibes.

So what’s driving the price right now? The strongest correlation gold has is an inverse relationship with real interest rates (TIPS). When real rates are high, holding gold is expensive—you’re giving up that yield for an asset that pays you nothing. But when real rates drop, suddenly gold looks attractive again. That’s the mechanism. That’s why gold moves.

But here’s the problem: by traditional metrics, gold looks really expensive right now.

Gold is currently trading at 17x CPI (the historical median is 3x). The gold-to-silver ratio is sitting at 83:1 (typical is 57:1). These are stretched valuations by any historical standard.

Does that mean gold will crash? No—gold almost never crashes. What it means is forward returns will likely be lower than the historical average. And consider this: since 1984, gold has returned about 6% less per year than equities, with roughly the same volatility. You’re taking equity-level risk for bond-level returns.

My take? The gold moment is probably over. The big move already happened. If you’re genuinely looking for catastrophe insurance, you need gold to be 15-20% of your portfolio for it to actually hedge anything. And at these valuations, that’s a tough bet. You might be better off waiting for Bitcoin to calm down—at least Bitcoin has asymmetry on its side.

→ In the full episode, I break down the exact mechanics of why gold correlates with real rates, walk through the historical data on gold’s performance during major crises, and explain why the “inflation hedge” narrative is more myth than reality.

Here’s the headline everyone saw: Eli Lilly briefly became the first drugmaker to hit a $1 trillion market cap, driven almost entirely by GLP-1 drugs like Zepbound and Mounjaro. Wall Street is pricing in a $150 billion market by 2030. But here’s what most investors are missing about why this is different from every other pharmaceutical boom:

GLP-1s have a churn rate of theoretically zero.

When you stop taking GLP-1s, you gain the weight back. This isn’t a cure—it’s a subscription. And the numbers back this up: 1 in 8 U.S. adults (12%) have taken a GLP-1 drug at some point, with about 6% currently using them. That’s not a niche market. That’s mainstream penetration with built-in retention mechanics that would make SaaS companies jealous.

Now enter the Trump administration’s TrumpRx program, which promises to offer GLP-1s at $245-350 per month (down from much higher out-of-pocket costs). Sounds great for access, right? Here’s the catch: demand already outstrips supply. Manufacturers have been scaling production aggressively, but they can’t keep up. Lower prices will likely increase demand further, which means expanded access could paradoxically create more shortages.

This is the supply-demand wrinkle nobody’s pricing in properly. When the pricing announcements first hit, Nova Nordisk and Eli Lilly shares fell—investors feared margin pressure. But then the market doubled down on the growth story, betting that expanded access will sustain long-term revenue even with price concessions.

Here’s what matters for investors: the exact price and coverage terms, the production commitments, and how private payers follow the government’s lead. Those technicalities will determine whether this becomes a genuine public health win or a painful lesson in unintended consequences.

→ In the full episode, we explain why this is one of the most economically interventionist policies of the Trump administration, break down the exact mechanics of how the TrumpRx pricing will work across different channels, and walk through the production constraints that could make or break this market over the next 24 months. Plus, I explain why the “churn rate = zero” insight changes how you should think about pharmaceutical valuations entirely.

Look, I could have written 3,000 more words here. I could have walked you through the full gold valuation models, explained why the Bretton Woods collapse still matters today, broken down Eli Lilly’s entire product pipeline, or dissected the exact supply chain bottlenecks in GLP-1 manufacturing.

But here’s the thing: this newsletter is the trailer. The podcast is the movie.

If you’re serious about understanding markets—not just reading headlines, but actually understanding the mechanisms, the historical context, the second-order effects that everyone else misses—then you need to be listening every week.

We’re not doing surface-level takes. We’re doing the deep work. The kind of analysis that actually changes how you think about risk, valuation, and where opportunities hide when everyone else is looking the wrong direction.

And if this was valuable? Share it. Send it to someone who’d benefit. Forward it to your group chat. Post it on Twitter. The only way this grows is if you help it grow.

See you next week.

— J&E

P.S. — Got a topic you want us to cover? A contrarian take you want challenged? Reply to this email. I read every single one.